3-Epidehydrotumulosic acid

CAS No. 167775-54-4

3-Epidehydrotumulosic acid( —— )

Catalog No. M31323 CAS No. 167775-54-4

3-Epidehydrotumulosic acid has inhibitory activity against AAPH-induced lysis of red blood cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1861 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    3-Epidehydrotumulosic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    3-Epidehydrotumulosic acid has inhibitory activity against AAPH-induced lysis of red blood cells.
  • Description
    3-Epidehydrotumulosic acid has inhibitory activity against AAPH-induced lysis of red blood cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    167775-54-4
  • Formula Weight
    484.7
  • Molecular Formula
    C31H48O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Haloxyfop

    (±)-Haloxyfop is a herbicide.

  • FIDAS-5

    FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.

  • JAK2 Inhibitor V

    NSC 42834(JAK2 Inhibitor V, Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.